CN Patent

CN107266435A — 细胞凋亡诱导剂的盐和晶形

Assigned to AbbVie Inc · Expires 2017-10-20 · 9y expired

What this patent protects

本发明涉及细胞凋亡诱导剂的盐和晶形。4‑(4‑{[2‑(4‑氯苯基)‑4,4‑二甲基环己‑1‑烯‑1‑基]甲基}哌嗪‑1‑基)‑N‑({3‑硝基‑4‑[(四氢‑2H‑吡喃‑4‑基甲基)氨基]苯基}‑磺酰基)‑2‑(1H‑吡咯并[2,3‑b]吡啶‑5‑基氧基)苯甲酰胺的盐和晶形是药物组合物的合适活性药物成分，该药物组合物可用于治疗特征在于一种或多种抗细胞凋亡Bcl‑2家族蛋白过度表达的疾病，例如癌症。

USPTO Abstract

本发明涉及细胞凋亡诱导剂的盐和晶形。4‑(4‑{[2‑(4‑氯苯基)‑4,4‑二甲基环己‑1‑烯‑1‑基]甲基}哌嗪‑1‑基)‑N‑({3‑硝基‑4‑[(四氢‑2H‑吡喃‑4‑基甲基)氨基]苯基}‑磺酰基)‑2‑(1H‑吡咯并[2,3‑b]吡啶‑5‑基氧基)苯甲酰胺的盐和晶形是药物组合物的合适活性药物成分，该药物组合物可用于治疗特征在于一种或多种抗细胞凋亡Bcl‑2家族蛋白过度表达的疾病，例如癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN107266435A
Jurisdiction
CN
Classification
—
Expires
2017-10-20
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.